No detectable beneficial systemic immunomodulatory effects of a specific synbiotic mixture in infants with atopic dermatitis.

L.B. van der Aa; R. Lutter; H.S.A. Heymans; B.S. Smids; G.H. Dekker; W.M.C van Aalderen; JH Sillevis Smitt; L.M.J. Knippels; J. Garssen; A.J. Nauta; A.B. Sprikkelman

No detectable beneficial systemic immunomodulatory effects of a specific synbiotic mixture in infants with atopic dermatitis.

L.B. van der Aa, R. Lutter, H.S.A. Heymans, B.S. Smids, G.H. Dekker, W.M.C van Aalderen, JH Sillevis Smitt, L.M.J. Knippels, J. Garssen, A.J. Nauta, A.B. Sprikkelman

extern

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

BACKGROUND: In a murine model of allergic inflammation, Bifidobacterium breve M-16V has been shown to reduce IL-4 and IgE by inducing IL-10 and IFN-gamma. However, it remains unknown whether this strain has the same effect in humans with allergic disease. OBJECTIVE: To determine the effects of Bifidobacterium breve M-16V combined with a prebiotic oligosaccharide mixture (synbiotic) on atopic markers, ex vivo cytokine production by peripheral blood mononuclear cells (PBMCs) and circulating regulatory T cell percentage in infants with atopic dermatitis. METHODS: In a double-blind, placebo-controlled multi-centre trial, 90 infants with atopic dermatitis, age

Original language	Undefined/Unknown
Pages (from-to)	531-9
Number of pages	9
Journal	Clinical and Experimental Allergy
Volume	42
Issue number	4
Publication status	Published - 2012

Cite this

van der Aa, L. B., Lutter, R., Heymans, H. S. A., Smids, B. S., Dekker, G. H., van Aalderen, W. M. C., Sillevis Smitt, JH., Knippels, L. M. J., Garssen, J., Nauta, A. J., & Sprikkelman, A. B. (2012). No detectable beneficial systemic immunomodulatory effects of a specific synbiotic mixture in infants with atopic dermatitis. Clinical and Experimental Allergy, 42(4), 531-9.

@article{f518c21cee4a4815895cfc741fe27ba9,

title = "No detectable beneficial systemic immunomodulatory effects of a specific synbiotic mixture in infants with atopic dermatitis.",

abstract = "BACKGROUND: In a murine model of allergic inflammation, Bifidobacterium breve M-16V has been shown to reduce IL-4 and IgE by inducing IL-10 and IFN-gamma. However, it remains unknown whether this strain has the same effect in humans with allergic disease. OBJECTIVE: To determine the effects of Bifidobacterium breve M-16V combined with a prebiotic oligosaccharide mixture (synbiotic) on atopic markers, ex vivo cytokine production by peripheral blood mononuclear cells (PBMCs) and circulating regulatory T cell percentage in infants with atopic dermatitis. METHODS: In a double-blind, placebo-controlled multi-centre trial, 90 infants with atopic dermatitis, age",

author = "{van der Aa}, L.B. and R. Lutter and H.S.A. Heymans and B.S. Smids and G.H. Dekker and {van Aalderen}, W.M.C and {Sillevis Smitt}, JH and L.M.J. Knippels and J. Garssen and A.J. Nauta and A.B. Sprikkelman",

year = "2012",

language = "Undefined/Unknown",

volume = "42",

pages = "531--9",

journal = "Clinical and Experimental Allergy",

issn = "0954-7894",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "4",

}

TY - JOUR

T1 - No detectable beneficial systemic immunomodulatory effects of a specific synbiotic mixture in infants with atopic dermatitis.

AU - van der Aa, L.B.

AU - Lutter, R.

AU - Heymans, H.S.A.

AU - Smids, B.S.

AU - Dekker, G.H.

AU - van Aalderen, W.M.C

AU - Sillevis Smitt, JH

AU - Knippels, L.M.J.

AU - Garssen, J.

AU - Nauta, A.J.

AU - Sprikkelman, A.B.

PY - 2012

Y1 - 2012

N2 - BACKGROUND: In a murine model of allergic inflammation, Bifidobacterium breve M-16V has been shown to reduce IL-4 and IgE by inducing IL-10 and IFN-gamma. However, it remains unknown whether this strain has the same effect in humans with allergic disease. OBJECTIVE: To determine the effects of Bifidobacterium breve M-16V combined with a prebiotic oligosaccharide mixture (synbiotic) on atopic markers, ex vivo cytokine production by peripheral blood mononuclear cells (PBMCs) and circulating regulatory T cell percentage in infants with atopic dermatitis. METHODS: In a double-blind, placebo-controlled multi-centre trial, 90 infants with atopic dermatitis, age

AB - BACKGROUND: In a murine model of allergic inflammation, Bifidobacterium breve M-16V has been shown to reduce IL-4 and IgE by inducing IL-10 and IFN-gamma. However, it remains unknown whether this strain has the same effect in humans with allergic disease. OBJECTIVE: To determine the effects of Bifidobacterium breve M-16V combined with a prebiotic oligosaccharide mixture (synbiotic) on atopic markers, ex vivo cytokine production by peripheral blood mononuclear cells (PBMCs) and circulating regulatory T cell percentage in infants with atopic dermatitis. METHODS: In a double-blind, placebo-controlled multi-centre trial, 90 infants with atopic dermatitis, age

M3 - Article

SN - 0954-7894

VL - 42

SP - 531

EP - 539

JO - Clinical and Experimental Allergy

JF - Clinical and Experimental Allergy

IS - 4

ER -